WO2021101519A1 - System and method for removal of immune inhibitors from biological fluids - Google Patents
System and method for removal of immune inhibitors from biological fluids Download PDFInfo
- Publication number
- WO2021101519A1 WO2021101519A1 PCT/US2019/062177 US2019062177W WO2021101519A1 WO 2021101519 A1 WO2021101519 A1 WO 2021101519A1 US 2019062177 W US2019062177 W US 2019062177W WO 2021101519 A1 WO2021101519 A1 WO 2021101519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target component
- capture
- body fluid
- capture support
- stnf
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 239000013060 biological fluid Substances 0.000 title description 2
- 239000003446 ligand Substances 0.000 claims abstract description 106
- 210000001124 body fluid Anatomy 0.000 claims abstract description 78
- 239000010839 body fluid Substances 0.000 claims abstract description 78
- 230000027455 binding Effects 0.000 claims description 85
- 230000014759 maintenance of location Effects 0.000 claims description 85
- 239000011324 bead Substances 0.000 claims description 83
- 210000004369 blood Anatomy 0.000 claims description 39
- 239000008280 blood Substances 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 32
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 238000001042 affinity chromatography Methods 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 10
- 239000011148 porous material Substances 0.000 claims description 9
- 229920000936 Agarose Polymers 0.000 claims description 8
- 230000001093 anti-cancer Effects 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000002591 computed tomography Methods 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 229920002684 Sepharose Polymers 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 3
- 238000005401 electroluminescence Methods 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 78
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 76
- 238000011282 treatment Methods 0.000 abstract description 51
- 206010028980 Neoplasm Diseases 0.000 abstract description 41
- 201000011510 cancer Diseases 0.000 abstract description 27
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 7
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 7
- -1 alanine amino acids Chemical class 0.000 description 32
- 238000002617 apheresis Methods 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 239000012530 fluid Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 241000282465 Canis Species 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
- 238000002386 leaching Methods 0.000 description 8
- 231100000682 maximum tolerated dose Toxicity 0.000 description 8
- 239000004417 polycarbonate Substances 0.000 description 8
- 229920000515 polycarbonate Polymers 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 101800001271 Surface protein Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 229960005386 ipilimumab Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002616 plasmapheresis Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000006268 reductive amination reaction Methods 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 235000004400 serine Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- IEJPPSMHUUQABK-UHFFFAOYSA-N 2,4-diphenyl-4h-1,3-oxazol-5-one Chemical compound O=C1OC(C=2C=CC=CC=2)=NC1C1=CC=CC=C1 IEJPPSMHUUQABK-UHFFFAOYSA-N 0.000 description 3
- HQWDKLAIDBOLFE-UHFFFAOYSA-M 2-fluoro-1-methylpyridin-1-ium;4-methylbenzenesulfonate Chemical compound C[N+]1=CC=CC=C1F.CC1=CC=C(S([O-])(=O)=O)C=C1 HQWDKLAIDBOLFE-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 229920001780 ECTFE Polymers 0.000 description 3
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108091005735 TGF-beta receptors Proteins 0.000 description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 239000012504 chromatography matrix Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 230000006028 immune-suppresssive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
- 102100036509 Erythropoietin receptor Human genes 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004425 Makrolon Substances 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 150000001510 aspartic acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 102000002467 interleukin receptors Human genes 0.000 description 2
- 108010093036 interleukin receptors Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012487 rinsing solution Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 229920000638 styrene acrylonitrile Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 108010059983 CCR Receptors Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 101100285408 Danio rerio eng2a gene Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000015278 OSM-LIF Receptors Human genes 0.000 description 1
- 108010064527 OSM-LIF Receptors Proteins 0.000 description 1
- 102000012547 Olfactory receptors Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 102000003987 Oncostatin M Receptors Human genes 0.000 description 1
- 108010082522 Oncostatin M Receptors Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100028927 Secretin receptor Human genes 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000011016 integrity testing Methods 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091005592 methylated proteins Proteins 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000027424 natriuretic peptide receptors Human genes 0.000 description 1
- 108091008599 natriuretic peptide receptors Proteins 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 108700027603 secretin receptor Proteins 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021572881A JP7159493B2 (en) | 2019-11-19 | 2019-11-19 | Systems and methods for removing immune inhibitors from biological fluids |
IL289438A IL289438B2 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
AU2019474912A AU2019474912B2 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
CN201980102088.9A CN114650852A (en) | 2019-11-19 | 2019-11-19 | System and method for removing immunosuppressive agents from biological fluids |
IL301912A IL301912A (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
PCT/US2019/062177 WO2021101519A1 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
EP19920634.3A EP3846875A4 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
CA3165330A CA3165330A1 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
KR1020227003407A KR102491518B1 (en) | 2019-11-19 | 2019-11-19 | Systems and methods for removing immunosuppressants from biological fluids |
KR1020237002011A KR20230016032A (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
CA3153685A CA3153685C (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
TW108142585A TWI762833B (en) | 2019-11-19 | 2019-11-22 | System and method for removal of immune inhibitors from biological fluids |
AU2022203249A AU2022203249B2 (en) | 2019-11-19 | 2022-05-16 | System and method for removal of immune inhibitors from biological fluids |
JP2022163897A JP2023015053A (en) | 2019-11-19 | 2022-10-12 | System and method for removal of immune inhibitors from biological fluids |
AU2023274130A AU2023274130A1 (en) | 2019-11-19 | 2023-11-29 | System and method for removal of immune inhibitors from biological fluids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/062177 WO2021101519A1 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021101519A1 true WO2021101519A1 (en) | 2021-05-27 |
Family
ID=75980821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/062177 WO2021101519A1 (en) | 2019-11-19 | 2019-11-19 | System and method for removal of immune inhibitors from biological fluids |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3846875A4 (en) |
JP (2) | JP7159493B2 (en) |
KR (2) | KR102491518B1 (en) |
CN (1) | CN114650852A (en) |
AU (3) | AU2019474912B2 (en) |
CA (2) | CA3165330A1 (en) |
IL (2) | IL301912A (en) |
WO (1) | WO2021101519A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
WO2022071960A1 (en) * | 2020-10-01 | 2022-04-07 | Immunicom, Inc. | Reduced leaching of a ligand |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1243298A1 (en) * | 1999-11-02 | 2002-09-25 | Kaneka Corporation | Filling out-flow preventing filter and absorber attached with it |
US20070083145A1 (en) * | 2005-10-12 | 2007-04-12 | Nikkiso Co. Ltd. | Blood purification apparatus and method for calculating a recirculation rate for the blood purification apparatus |
US20140074007A1 (en) * | 2012-09-11 | 2014-03-13 | Gary L. McNeil | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source |
US20140303542A1 (en) * | 2013-03-14 | 2014-10-09 | Brian J. LeBerthon | Method and device for treating cancer |
US20150093289A1 (en) * | 2003-01-17 | 2015-04-02 | Aethlon Medical, Inc. | Method for removal of viruses from blood by lectin affinity hemodialysis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025228A1 (en) * | 1995-02-16 | 1996-08-22 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | ADSORBENT FOR TUMOR NECROSIS FACTOR α, METHOD OF REMOVAL BY ADSORPTION, AND ADSORPTION DEVICE USING SAID ADSORBENT |
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
AU2008293431B2 (en) * | 2007-08-31 | 2013-07-04 | Cytopherx, Inc. | Selective cytopheresis devices and related methods thereof |
WO2015130956A2 (en) | 2014-02-28 | 2015-09-03 | Exosome Sciences, Inc. | Brain specific exosome based diagnostics and extracorporeal therapies |
CN106457205B (en) * | 2014-07-22 | 2020-09-22 | 旭化成医疗株式会社 | Adsorption material for removing histone and biological source liquid purifying equipment |
EP3490696B1 (en) * | 2016-07-28 | 2023-09-06 | Captec Medical KFT. | Flow capture device for removing cells from blood |
US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
DE102018104177A1 (en) * | 2018-02-23 | 2019-08-29 | B. Braun Avitum Ag | Apparatus for removing noxious substances from blood, extracorporeal perfusion system comprising such a device and method for producing such a device |
-
2019
- 2019-11-19 WO PCT/US2019/062177 patent/WO2021101519A1/en unknown
- 2019-11-19 KR KR1020227003407A patent/KR102491518B1/en active IP Right Grant
- 2019-11-19 IL IL301912A patent/IL301912A/en unknown
- 2019-11-19 EP EP19920634.3A patent/EP3846875A4/en active Pending
- 2019-11-19 KR KR1020237002011A patent/KR20230016032A/en not_active Application Discontinuation
- 2019-11-19 CN CN201980102088.9A patent/CN114650852A/en active Pending
- 2019-11-19 CA CA3165330A patent/CA3165330A1/en active Pending
- 2019-11-19 AU AU2019474912A patent/AU2019474912B2/en active Active
- 2019-11-19 JP JP2021572881A patent/JP7159493B2/en active Active
- 2019-11-19 IL IL289438A patent/IL289438B2/en unknown
- 2019-11-19 CA CA3153685A patent/CA3153685C/en active Active
-
2022
- 2022-05-16 AU AU2022203249A patent/AU2022203249B2/en active Active
- 2022-10-12 JP JP2022163897A patent/JP2023015053A/en active Pending
-
2023
- 2023-11-29 AU AU2023274130A patent/AU2023274130A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1243298A1 (en) * | 1999-11-02 | 2002-09-25 | Kaneka Corporation | Filling out-flow preventing filter and absorber attached with it |
US20150093289A1 (en) * | 2003-01-17 | 2015-04-02 | Aethlon Medical, Inc. | Method for removal of viruses from blood by lectin affinity hemodialysis |
US20070083145A1 (en) * | 2005-10-12 | 2007-04-12 | Nikkiso Co. Ltd. | Blood purification apparatus and method for calculating a recirculation rate for the blood purification apparatus |
US20140074007A1 (en) * | 2012-09-11 | 2014-03-13 | Gary L. McNeil | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source |
US20140303542A1 (en) * | 2013-03-14 | 2014-10-09 | Brian J. LeBerthon | Method and device for treating cancer |
Non-Patent Citations (54)
Title |
---|
"Genbank", Database accession no. AQY77150.1 |
ADERKA, D. ET AL., CANCER RES, vol. 51, 1991, pages 5602 - 5607 |
ADERKA, D. ET AL., J CLIN INVEST, vol. 101, 1998, pages 650 - 659 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 |
ASHMAN, K. ET AL., PROTEIN ENG, vol. 2, 1989, pages 387 - 391 |
BERBEROGLU, U. ET AL., INT J BIOL MARKERS, vol. 19, 2004, pages 130 - 134 |
BOLDRINI, L. ET AL., BR J CANCER, vol. 83, 2000, pages 480 - 486 |
BOSTICK ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 304, 2003, pages 320 |
CARSWELL, E. A. ET AL., PROC NATL ACAD SCI U S A, vol. 72, 1975, pages 3666 - 3670 |
COLEY, W. B., CLIN ORTHOP RELAT RES, 1991, pages 3 - 11 |
DEROOSE, J. P. ET AL., ANN SURG ONCOL, vol. 19, 2012, pages 627 - 635 |
DI GIORGIO, A. ET AL., INT SURG, vol. 77, 1992, pages 256 - 260 |
ENGELMANN, H. ET AL., J BIOL CHEM, vol. 265, 1990, pages 1531 - 1536 |
GATANAGA, T. ET AL., LYMPHOKINE RES, vol. 9, 1990, pages 225 - 229 |
GATANAGA, T. ET AL., PROC NATL ACAD SCI U S A, vol. 87, 1990, pages 8781 - 8784 |
GOOSSENS, V. ET AL., PROC. NATL ACAD. SCI. USA, vol. 92, 1995, pages 8115 - 8119 |
GOOSSENS, V., PROC. NATL ACAD. SCI. U S A, vol. 92, 1995, pages 8115 - 8119 |
GUO, D. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 207, 1995, pages 927 - 932 |
HAMID, O. ET AL., N ENGL J MED, vol. 369, 2013, pages 134 - 144 |
HERBST, R. S. ET AL., NATURE, vol. 515, 2014, pages 558 - 562 |
HODI, F. S. ET AL., N ENGL J MED, vol. 363, 2010, pages 711 - 723 |
HORWITZ, A. H. ET AL., PROTEIN EXPR PURIF, vol. 8, 1996, pages 28 - 40 |
ISRAEL, L. ET AL., CANCER, vol. 40, 1977, pages 3146 - 3154 |
ISRAEL, L. ET AL., LANCET, vol. 2, 1976, pages 642 - 643 |
LANGKOPF, F.ATZPODIEN, J., LANCET, vol. 344, 1994, pages 57 - 58 |
LI, C. B. ET AL., SCI CHINA B, vol. 35, 1992, pages 319 - 328 |
LI, H. ET AL., WORLD J MICROBIOL BIOTECHNOL, vol. 35, 2019, pages 27 |
LIPPONEN, P. K. ET AL., EUR J CANCER, vol. 29A, 1992, pages 69 - 75 |
MA, D.GU, M. J., J TONGJI MED UNIV, vol. 11, 1991, pages 235 - 239 |
MICHALAKI, V. ET AL., BR J CANCER, vol. 90, 2004, pages 2312 - 2316 |
MORI, T. ET AL., GENE, vol. 144, 1994, pages 289 - 293 |
MULLER, H. E., PATHOL MICROBIOL (BASEL, vol. 40, 1974, pages 297 - 304 |
MULLER, R. ET AL., FEBS LETT, vol. 197, 1986, pages 99 - 104 |
OZAKILEONARD, J.BIOL. CHEM, vol. 277, 2002, pages 29355 - 29353 |
PASTRNAK, A.JANSA, P., ACTA UNIV PALACKI OLOMUC FAC MED, vol. 124, 1989, pages 7 - 71 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PEARSON, METHODS MOL BIOL., vol. 132, 2000, pages 185 |
RIBAS, A.WOLCHOK, J. D., SCIENCE, vol. 359, 2018, pages 1350 - 1355 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2007 |
SCHALL, T. J. ET AL., CELL, vol. 61, 1990, pages 361 - 370 |
SELINSKY, C. L. ET AL., IMMUNOLOGY, vol. 94, 1998, pages 88 - 93 |
SELINSKY, C. L.HOWELL, M. D., CELL IMMUNOL, vol. 200, 2000, pages 81 - 87 |
SMITH ET AL., J. MOL. BIOL., vol. 147, 1981, pages 195 |
SU, X. ET AL., BIOTECHNIQUES, vol. 13, 1992, pages 756 - 762 |
TALMADGE, J. E. ET AL., CANCER RES, vol. 47, 1987, pages 2563 - 2570 |
TANG, P. ET AL., BIOCHEMISTRY, vol. 35, 1996, pages 8216 - 8225 |
TOPALIAN, S. L. ET AL., J CLIN ONCOL, vol. 32, 2014, pages 1020 - 1030 |
TOPALIAN, S. L. ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 2454 |
VERHOEF, C. ET AL., CURR TREAT OPTIONS ONCOL, vol. 8, 2007, pages 417 - 427 |
VIAC, J. ET AL., EUR J CANCER, vol. 32A, 1996, pages 447 - 449 |
WANG, X.LIN, Y., ACTA PHARMACOL SIN, vol. 29, 2008, pages 1275 - 1288 |
XANTHOULEA, S. ET AL., J EXP MED, vol. 200, 2004, pages 367 - 376 |
XIANG, J. ET AL., J BIOTECHNOL, vol. 53, 1997, pages 3 - 12 |
YATES, J. W.HOLLAND, J. F., CANCER, vol. 32, 1973, pages 1490 - 1498 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
WO2022071960A1 (en) * | 2020-10-01 | 2022-04-07 | Immunicom, Inc. | Reduced leaching of a ligand |
US11458236B2 (en) | 2020-10-01 | 2022-10-04 | Immunicom, Inc. | Reduced leaching of a ligand |
Also Published As
Publication number | Publication date |
---|---|
KR20220039724A (en) | 2022-03-29 |
JP2022535604A (en) | 2022-08-09 |
CA3165330A1 (en) | 2021-05-27 |
KR20230016032A (en) | 2023-01-31 |
CN114650852A (en) | 2022-06-21 |
AU2022203249B2 (en) | 2023-08-31 |
JP2023015053A (en) | 2023-01-31 |
EP3846875A1 (en) | 2021-07-14 |
IL289438B1 (en) | 2023-05-01 |
IL301912A (en) | 2023-06-01 |
IL289438A (en) | 2022-02-01 |
AU2019474912B2 (en) | 2022-02-17 |
AU2023274130A1 (en) | 2023-12-21 |
EP3846875A4 (en) | 2021-07-14 |
AU2019474912A1 (en) | 2022-01-06 |
IL289438B2 (en) | 2023-09-01 |
AU2022203249A1 (en) | 2022-06-23 |
CA3153685A1 (en) | 2021-05-27 |
JP7159493B2 (en) | 2022-10-24 |
CA3153685C (en) | 2022-10-11 |
KR102491518B1 (en) | 2023-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022203249B2 (en) | System and method for removal of immune inhibitors from biological fluids | |
EP2717941B1 (en) | Treating cancer | |
KR101703785B1 (en) | Treating inflammatory conditions | |
US20180038860A1 (en) | Treating cancer | |
US20120323158A1 (en) | Extracorporeal immunoadsorption treatment | |
US20220288294A1 (en) | System and method for removal of immune inhibitors from biological fluids | |
TWI762833B (en) | System and method for removal of immune inhibitors from biological fluids | |
US11957825B2 (en) | Modified TNF as a capture ligand | |
WO2012172343A2 (en) | Treating primary sclerosing cholangitis | |
EP2718313B1 (en) | Treating respiratory conditions | |
WO2012172340A2 (en) | Treating mental disorders | |
JP2009240491A (en) | Operation method of body fluid purification system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019920634 Country of ref document: EP Effective date: 20200929 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19920634 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021572881 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019474912 Country of ref document: AU Date of ref document: 20191119 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227003407 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3153685 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |